China’s mRNA Vaccine Industry: A Latecomer’s Prospects
This article was originally posted on Pharma Boardroom May 31, 2023 | Justin Wu, 2023 Spring Intern, Bridge Consulting Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of the pandemic in the hope of securing domestic […]